DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR), a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical
device industries, today announced it has signed a three-year agreement
with Pfizer Inc. (NYSE:PFE). Under the terms of the agreement, Pfizer
has the right to extend the term for up to an additional two years.
Financial details of the agreement were not disclosed.
The new agreement builds on the companies' existing relationship, under
which ICON provides global expertise in the planning, execution,
management and conduct of clinical trials.
Ciaran Murray, ICON's CEO, commented: "The progression of our
relationship with Pfizer is a recognition of ICON's capabilities in
supporting drug development efforts. We look forward to continuing our
relationship with Pfizer to help advance its development pipeline and
innovation in the drug development process."
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 89 locations in 37 countries and
has approximately 12,200 employees. Further information is available at www.iconplc.com.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20160610005206/en/
ICON
Investor Relations
1-888-381-7923
or
Brendan
Brennan
Chief Financial Officer
+ 353 -1-291-2000
or
Simon
Holmes
EVP Investor Relations and Corporate Development
+ 353
-1-291-2000
Source: ICON plc
News Provided by Acquire Media
